What is EpicentRx?
Headquartered in La Jolla, California, EpicentRx is a biopharmaceutical company dedicated to advancing immuno-oncology. The company's core mission revolves around developing pharmaceuticals designed to selectively target and eliminate tumor cells while minimizing toxicity to patients. This focus positions EpicentRx at the forefront of precision medicine, aiming to provide more effective and safer treatment options for cancer patients. Their approach leverages cutting-edge research in the complex field of cancer immunology.
How much funding has EpicentRx raised?
EpicentRx has raised a total of $35M across 1 funding round:
Series D
$35M
Series D (2019): $35M with participation from Biotech Alliances International
Key Investors in EpicentRx
Biotech Alliances International
Biotech Alliances International is a Miami-based life science advisory firm specializing in strategic insights, capital raising, and M&A for biotechnology, pharmaceutical, and healthcare companies. They leverage deep industry knowledge and a global network to connect innovators with capital and strategic opportunities.
What's next for EpicentRx?
The recent major strategic investment signals a pivotal growth phase for EpicentRx. With substantial capital infusion, the company is poised to accelerate its research and development pipeline, potentially bringing its novel immuno-oncology therapies closer to clinical trials and market approval. This strategic backing will likely enable EpicentRx to scale its operations, expand its scientific team, and forge key partnerships within the pharmaceutical and biotechnology sectors. The company's trajectory suggests a strong emphasis on translating scientific breakthroughs into tangible patient benefits, reinforcing its commitment to combating cancer.
See full EpicentRx company page
